On November 18, huadong medicine (000963.SZ) announced that its holding subsidiary zhejiang daor biological technology co., Ltd. (referred to as "daor biology") recently received the "Drug Clinical Trial Approval Notice" (Notice Number: 2024LP02586) issued by the National Medical Products Administration (NMPA). The clinical trial application for DR10624 injection submitted by daor biology has been approved.

DR10624 is a long-acting triple-target agonist independently developed by daor biology, targeting FGFR1c/Klothoβ (FGF21R), GLP-1 receptor (GLP-1R), and GCG receptor (GCGR) as a candidate innovative protein drug. DR10624 is composed of N-terminal targeting GLP1R/GCGR chimeric peptide segment fused with engineered IgG1 Fc, and a recombinant FGF21 mutant fused at the C-terminal of Fc. Preclinical studies have shown that DR10624 has strong metabolic regulation and improvement effects.